## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. ICU Medical (ICUI): Reassessing Valuation After a 22% One-Month Share Price Rebound**
- Source: Sahm | 20251204T041120 | Somewhat-Bullish | Relevance: 98%
- ICU Medical (ICUI) has seen its stock rebound by 22% over the past month, prompting a reassessment of its valuation. While one narrative suggests the company is 18.9% undervalued with a fair value of $180.83 due to improving margins and integration synergies, another perspective highlights that its 1.6x price-to-sales multiple is above its 1.0x fair ratio, despite being below industry averages. Investors are left to weigh whether the recent rally fully accounts for the recovery or if further upside exists.

**2. KeyBanc reiterates Overweight rating on ICU Medical stock, sees growth**
- Source: Investing.com | 20251205T041120 | Bullish | Relevance: 98%
-  KeyBanc has reaffirmed its Overweight rating and $175.00 price target for ICU Medical (NASDAQ:ICUI), anticipating continued revenue growth and margin expansion. This positive outlook follows meetings with the company's CEO and solid third-quarter results for 2025 where ICU Medical surpassed analyst expectations for both EPS and revenue. The firm expects mid-single-digit growth driven by recent successes and increased placements of next-generation pumps, with further upside potential in gross margin improvements and leverage reduction through potential divestitures.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 17.7x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 17.7 |
| Current P/E | 18.9 |
| YoY Growth | 6.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.7% to -4.1% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.53), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.13% (CS: 13) | Weak |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.074x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $142.51
- **Stop Loss:** $132.09 (7.3% risk)
- **Target:** $152.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $6,697.97
- **Portfolio %:** 6.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*